申请人:Otsuka Pharmaceutical Company, Limited
公开号:US04824834A1
公开(公告)日:1989-04-25
Pyrazolotriazine compounds of the formula: ##STR1## wherein R.sup.1 is OH or alkanoyloxy; R.sup.2 is H, OH, or SH; R.sup.3 is (1) unsaturated N- or S-containing heterocyclic group optionally having 1-2 substituents of halogen, nitro or phenylthio, (2) naphthyl, (3) phenyl optionally having 1-3 substituents of (i) alkyl, (ii) phenyl, (iii) alkoxycarbonyl, (iv) cyano, (v) nitro, (vi) alkoxy, (vii) phenylalkoxy (viii) phenylthio-alkyl, (ix) phenoxy, (x) ##STR2## R is alkyl, halo-substituted alkyl, phenyl optionally having 1-3 substituents, or pyridyl, and l is 0, 1 or 2, (xi) halogen, (xii) phenylalkyl, (xiii) carboxy, (xiv) alkanoyl, (xv) benzoyl optionally having 1-3 substituents, (xvi) amino, (xvii) OH, (xviii) alkanoyloxy, (xix) ##STR3## or (xx) ##STR4## (A is alkylene), said compounds having a xanthine oxidase inhibitory activity and are useful for the prophylaxis and treatment of gout.
该配方的吡唑三嗪化合物:##STR1## 其中R.sup.1为OH或烷酰氧基; R.sup.2为H,OH或SH; R.sup.3为(1)不饱和N-或S-含杂环基,可选择具有1-2个卤素,硝基或苯基硫代基的取代基,(2)萘基,(3)苯基,可选择具有1-3个取代基的(i)烷基,(ii)苯基,(iii)烷氧羰基,(iv)氰基,(v)硝基,(vi)烷氧基,(vii)苯基烷氧基(viii)苯基硫代烷基,(ix)苯氧基,(x)##STR2## R为烷基,卤代烷基,苯基可选择具有1-3个取代基或吡啶基,l为0、1或2,(xi)卤素,(xii)苯基烷基,(xiii)羧基,(xiv)烷酰基,(xv)苯甲酰基,可选择具有1-3个取代基,(xvi)氨基,(xvii)OH,(xviii)烷酰氧基,(xix)##STR3## 或(xx)##STR4##(A为烷基),这些化合物具有黄嘌呤氧化酶抑制活性,用于痛风的预防和治疗。